Herantis Pharma’s Annual Report 2018 published
Herantis Pharma Plc
Company release 20 March 2019 at 9:00 am
Herantis Pharma Plc’s Annual Report for the year 2018 has been published today. The Annual Report contains financial statements and the report of the Board of Directors. The Annual Report is available in PDF format in Finnish and English as an appendix to this release and on the company’s web site at https://herantis.com in section Investors – Financial information.
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson's disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.